You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Biogen Idec gains on new MS drug’s sales

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Suzanne Kreiter/Globe Staff/File

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.

Continue reading below

Biogen Idec Inc. shares climbed 4.9 percent to a record $223.98 before closing at $223.61, up
­4.7­ percent. The Weston company’s new multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis and Sanofi, Bloomberg News reported, suggesting the treatment may beat sales estimates for the year. Total­ prescriptions more than doubled during the third week of the launch to 730 from 332 the previous week, according to Wells Fargo & Co.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of